Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;22(3):263-77.
doi: 10.1007/s00540-008-0626-2. Epub 2008 Aug 7.

Anesthetics, immune cells, and immune responses

Affiliations
Review

Anesthetics, immune cells, and immune responses

Shin Kurosawa et al. J Anesth. 2008.

Abstract

General anesthesia accompanied by surgical stress is considered to suppress immunity, presumably by directly affecting the immune system or activating the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Along with stress such as surgery, blood transfusion, hypothermia, hyperglycemia, and postoperative pain, anesthetics per se are associated with suppressed immunity during perioperative periods because every anesthetic has direct suppressive effects on cellular and neurohumoral immunity through influencing the functions of immunocompetent cells and inflammatory mediator gene expression and secretion. Particularly in cancer patients, immunosuppression attributable to anesthetics, such as the dysfunction of natural killer cells and lymphocytes, may accelerate the growth and metastases of residual malignant cells, thereby worsening prognoses. Alternatively, the anti-inflammatory effects of anesthetics may be beneficial in distinct situations involving ischemia and reperfusion injury or the systemic inflammatory response syndrome (SIRS). Clinical anesthesiologists should select anesthetics and choose anesthetic methods with careful consideration of the clinical situation and the immune status of critically ill patients, in regard to long-term mortality, morbidity, and the optimal prognosis.

PubMed Disclaimer

References

    1. Int Immunopharmacol. 2005 Sep;5(10):1519-22 - PubMed
    1. Cancer. 1997 Feb 1;79(3):474-81 - PubMed
    1. Anesth Analg. 2004 Apr;98(4):1086-1092 - PubMed
    1. Nat Rev Immunol. 2006 Mar;6(3):173-82 - PubMed
    1. J Muscle Res Cell Motil. 2003;24(2-3):219-49 - PubMed

MeSH terms

LinkOut - more resources